Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma
Synlogic, Inc. (SYBX)
Last synlogic, inc. earnings: 3/12 04:19 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.synlogictx.com/news-and-events/news-releases
Company Research
Source: PR Newswire
CAMBRIDGE, Mass., Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial. SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient's immune response.SYNB1891 is being advanced due to acceptable safety at doses evaluated to date, intratumoral injection feasibility, successful escalation to clinically relevant dose levels, and evidence of target engagement and immune system upregulation."Our goal is to bring the benefits of immunotherapy to patients fighting cancer who do not have the option of immunotherapies today," said Aoife Brennan, M.B. Ch.B., Synlogic's President and Chief Executive Officer
Show less
Read more
Impact Snapshot
Event Time:
SYBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYBX alerts
High impacting Synlogic, Inc. news events
Weekly update
A roundup of the hottest topics
SYBX
News
- Synlogic, Inc. (NASDAQ: SYBX) was upgraded by analysts at HC Wainwright from a "sell" rating to a "neutral" rating.MarketBeat
- Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Synlogic Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
- Synlogic Adopts Limited Duration Stockholders Rights Plan [Yahoo! Finance]Yahoo! Finance
- Synlogic Adopts Limited Duration Stockholders Rights PlanGlobeNewswire
SYBX
Earnings
- 11/9/23 - Miss
SYBX
Sec Filings
- 4/22/24 - Form 144
- 4/18/24 - Form SC
- 4/4/24 - Form 4
- SYBX's page on the SEC website